{Reference Type}: Journal Article
{Title}: Systemic therapy landscape of advanced prostate cancer.
{Author}: Paul AK;Melson JW;Hirani S;Muthusamy S;
{Journal}: Adv Cancer Res
{Volume}: 161
{Issue}: 0
{Year}: 2024
{Factor}: 5.767
{DOI}: 10.1016/bs.acr.2024.04.004
{Abstract}: Prostate cancer is the most commonly diagnosed cancer in American men and 2nd leading cause of cancer-related deaths in the United States. Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cancer. Over the past several decades a number of new therapeutics, such as novel androgen receptor pathway inhibitors, targeted agents and radionuclide therapies, have been introduced for the treatment of prostate cancers. These agents have been demonstrated to improve clinical outcomes of prostate cancer patients in randomized clinical trials. In addition, new therapeutic strategies, such as early intensification of ADT, novel treatment combinations, and treatment sequencing, are expected to improve outcomes further. In this clinical review, we discuss the changing treatment landscape for advanced prostate cancer with a focus on new therapeutics.